# A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

> **NCT03822832** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 51 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** BI 655130
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03822832
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2020-01-17
- **Final completion:** 2020-07-22
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822832, "A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03822832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*